PA1-020

antibody from Invitrogen Antibodies

Targeting: FKBP5 FKBP51, FKBP54, P54, PPIase, Ptg-10

Western blot

Antibody data

Submit

Validation data

Product number: PA1-020 - Provider product page
Provider: Invitrogen Antibodies
Product name: FKBP5 Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Synthetic peptide
Description: PA1-020 detects FK506 binding protein 51 kDa (FKBP51) in canine, hamster, human, mouse and rat tissues. PA1-020 has been successfully used in Western blot procedures. By Western blot, this antibody detects an ~51 kDa protein representing FKBP51 in HeLa cell lysate. By Western blot PA1-020 also detects FKBP51 in whole tissue extracts from rat kidney and rat and mouse testes. The PA1-020 immunogen is a synthetic peptide corresponding to the residues C(394) Q K K A K E H N E R D R R(407) of human FKBP51. There is a single amino acid substitution (K396 to R396) in this domain between human and mouse FKBP51 protein. PA1-020 immunizing peptide (Cat. # PEP-078) is available for use in neutralization and control experiments.
Reactivity: Human, Mouse, Rat, Canine, Hamster
Host: Rabbit
Isotype: IgG
Vial size: 100 µg
Concentration: 1 mg/mL
Storage: -20°C, Avoid Freeze/Thaw Cycles

FKBP5 protein structure - PA1-020 shown in red.

Supportive validation

Supportive validation

Supportive validation

Supportive validation

Supportive validation

Supportive validation

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6. WD increases FKBP51 protein levels in the hippocampus. A , Representative Western blot shows increased FKBP51 levels in the brains of the rats that consumed the WD. B , Analyses showed a significant main effect of the diet on brain FKBP51 levels (diet effect: F (1,19) = 15.45, p = 0.0009), PS exposure ( F (1,19) = 0.51, p = 0.49), or interaction between diet and PS exposure ( F (1,19) = 0.42, p = 0.52) did not show significant main effects on FKBP51 levels. C , Representative blot from micropunched anxiety-related brain regions showed distinctive FKBP51 levels. D , Analyses revealed a significant increase in FKBP51 levels in the hippocampus of the WDE rats when compared with CDE rats ( F (1,16) = 9.88; p = 0.0063, p = 0.021). Diet did not alter FKBP51 levels in the amygdala or medial prefrontal cortex. Although it did not reach statistical significance, we found a trend for more prefrontal cortex FKBP51 levels when compared with the amygdala and the hippocampus ( F (2,16) = 3.58, p = 0.052). No significant interactions between diet and the studied brain regions were revealed ( F (2,16) = 2.44, p = 0.12). Data are expressed as the mean +- SEM. * p < 0.05. Amygdala (AMY), n = 3-4 rats; medial prefrontal cortex (mPFC), n = 3-4; HPC, n = 4-5.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4. Ovariectomized female FBN-ARO-KO mice have diminished astrocyte A2 phenotype 7 d after GCI. Aa , Astrocyte PAN-reactive, A1-specific, and A2-specific phenotypes were determined by Western blot analysis with purified astrocyte lysates from ovariectomized female brains 7 d after GCI reperfusion. Ab , Levels of the examined markers for different astrocyte phenotypes were quantitatively analyzed. N = 3. B , IHC analysis for astrocyte A1 phenotype by double staining of the selected astrocyte A1 marker C3D with GFAP. Ca , IHC examination for astrocyte A2 phenotype using A2-specific marker S100A10 and GFAP double staining. Cb , Percentage changes of S100A10 in FBN-ARO-KO+GCI mice versus FLOX+GCI mice were quantified. N = 4. Values are mean +- SEM of determinations from each group. * p < 0.05 versus FLOX+Sham. # p < 0.05 versus FLOX+GCI. ND, Nondetectable.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 Hemin increases FKBP51 expression under Dexamethasone stimulation. ( A ) Western blot analysis showing FKBP51 and FKBP52 expression in PC3 cells treated with Hemin (80 muM for 24 h), Dex (10 nM for 6 h post Hemin/PBS 24-h treatment), the combination of both drugs, or PBS as control. Total protein was extracted and protein expression was analyzed by western blotting using specific antibodies. GAPDH levels are shown as control for equal loading. Protein quantification was performed by densitometry analysis using ImageJ software and bands were normalized to GAPDH and control. ( B ) FKBP51/FKBP52 ratio was calculated for each condition. One representative from at least three independent experiments is shown.